ClinicalTrials.gg
RecruitingNCT04994756STARUpdated Dec 24, 2025

Stroke Thrombectomy and Aneurysm Registry

An observational study in Stroke, Thromboses, Intracranial and Aneurysm, Brain, sponsored by Medical University of South Carolina. Recruiting at 63 sites in 9 countries. Open to participants aged 1 Year to 120 Years. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Medical University of South Carolina · Observational

From the registry’s dates

  • Started Sep 2019; still recruiting 7 years 1 month later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40,000
Ages
1 Year to 120 Years
Sex
All
01

Study summary

This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. This information is used to help predict outcomes that undergo an operation for treatment of the above-listed brain injuries. Additionally, the information is used to compare techniques and devices' effects on technical and clinical outcomes.

02

Conditions studied

  • Stroke
  • Thromboses, Intracranial
  • Aneurysm, Brain
03

In context

Stroke

8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.

This study's planned enrollment of 40,000 is above the median of 152 across 1,968 observational studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Medical University of South Carolina is the lead sponsor of 874 studies on the registry; 166 are open to participants now.

Of its 131 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any patients between 1 and 120 years of age, undergoing surgical intervention for central nervous system vascular lesions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Undergoing surgical intervention for central nervous system vascular lesion
  • Between 1 and 120 years of age

Exclusion criteria

Exclusion Criteria:

  • No exclusion criteria
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40,000 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes

Groups and cohorts

  • Stroke

    Procedure: Stroke/Thrombectomy/Aneurysm-specific surgical procedures

  • Thrombectomy

    Procedure: Stroke/Thrombectomy/Aneurysm-specific surgical procedures

  • Aneurysm

    Procedure: Stroke/Thrombectomy/Aneurysm-specific surgical procedures

Interventions

  • ProcedureStroke/Thrombectomy/Aneurysm-specific surgical procedures

    Participants are retrospectively and/or prospectively entered into registry based on disease indication and respective surgical procedure.

06

What researchers measure

Primary outcomes

  1. Post-procedure hemorrhage rate changes

    Researchers examine changes in hemorrhage rates in post-stroke patients

    Time frame: 90 days

  2. Occlusion rates

    Measure of how thrombectomy procedure success in relation to reduced occlusion

    Time frame: 90 days

  3. Complication rates

    Measure of post-procedure complication rates in stroke/aneurysm patients

    Time frame: 90 days

  4. Retreatment rates

    Measure of patient retreatment post-procedure

    Time frame: 90 days

07

Study locations

63 of 63 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Jan 2055, 423 months after the start.

Of 835 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 423 months is above that.

Counting every sponsor, half of 897 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2021
First posted
Aug 6, 2021
StartActual
Sep 17, 2019
Primary completionEst.
Jan 1, 2055
CompletionEst.
Jan 1, 2055
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04994756
Responsible party
Alejandro Spiotta (Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Aug 6, 2021
Start date
Sep 17, 2019
Primary completion
Jan 1, 2055 (estimated)
Completion
Jan 1, 2055 (estimated)
Last update
Dec 24, 2025

Study contacts

Alejandro M Spiotta, MD
Contact
spiotta@musc.edu
843-792-9226
Meredith Robinson, MS
Contact
robme@musc.edu
843-792-3164
Meredith Robinson, MS
study director · Medical University of South Carolina

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion